E3 ligase Ligand 14 is primarily utilized in the field of targeted protein degradation, specifically in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a key component that binds to E3 ubiquitin ligases, enabling the formation of a ternary complex with the target protein of interest. This interaction facilitates the ubiquitination of the target protein, marking it for degradation by the proteasome. Its application is significant in drug discovery, particularly for targeting undruggable proteins or those resistant to traditional inhibitors. By leveraging this ligand, researchers can design molecules that selectively degrade disease-causing proteins, offering potential therapeutic strategies for cancer, neurodegenerative disorders, and other diseases. Additionally, it is used in chemical biology studies to explore protein function and validate drug targets.